Is immune effector cell-associated enterocolitis a CAR T-cell lymphoproliferative disorder?
Kayra Somay, Hülya Azaklı, Joeffrey Chahine, Thomas Loughney, Metin Özdemirli
Abstract
We have read the recent article titled “Immune Effector Cell-Associated Enterocolitis Following Chimeric Antigen Receptor T-Cell Therapy in Multiple Myeloma”, by Fortuna et al. with great interest [ 1 ]. We found the article to be both comprehensive and highly valuable, especially in view of the current paucity of information on side effects of CAR T-cell therapies. However, we would like to offer additional observations that we believe are critical for a more accurate understanding of this condition. While the review acknowledges the risk of CAR T-cell lymphoma, we believe that indolent CAR T- cell lymphoproliferative disorders remain underrecognized and warrant greater emphasis due to their clinical significance.